A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors

Isabella Orienti, Federica Francescangeli, Maria Laura De Angelis, Katia Fecchi, Lucilla Bongiorno-Borbone, Michele Signore, Angelo Peschiaroli, Alessandra Boe, Alessandro Bruselles, Angelita Costantino, Adriana Eramo, Valentina Salvati, Giovanni Sette, Paola Contavalli, Lello Zolla, Toshihiko Oki, Toshio Kitamura, Massimo Spada, Alessandro Giuliani, Marta BaiocchiFilippo La Torre, Gerry Melino, Marco Tartaglia, Ruggero De Maria, Ann Zeuner

Research output: Contribution to journalArticle

Abstract

Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological profile, but also by a low bioavailability that hindered its clinical efficacy in former clinical trials. We developed a new formulation of fenretinide complexed with 2-hydroxypropyl-beta-cyclodextrin (nanofenretinide) characterized by an increased bioavailability and therapeutic efficacy. Nanofenretinide was active in cell lines derived from multiple solid tumors, in primary spheroid cultures and in xenografts of lung and colorectal cancer, where it inhibited tumor growth independently from the mutational status of tumor cells. A global profiling of pathways activated by nanofenretinide was performed by reverse-phase proteomic arrays and lipid analysis, revealing widespread repression of the mTOR pathway, activation of apoptotic, autophagic and DNA damage signals and massive production of dihydroceramide, a bioactive lipid with pleiotropic effects on several biological processes. In cells that survived nanofenretinide treatment there was a decrease of factors involved in cell cycle progression and an increase in the levels of p16 and phosphorylated p38 MAPK with consequent block in G0 and early G1. The capacity of nanofenretinide to induce cancer cell death and quiescence, together with its elevated bioavailability and broad antitumor activity indicate its potential use in cancer treatment and chemoprevention.

Original languageEnglish
Pages (from-to)529
JournalCell death & disease
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 23 2019

Fingerprint

Fenretinide
Biological Availability
Neoplasms
Biological Phenomena
Lipids
Retinoids
Chemoprevention
p38 Mitogen-Activated Protein Kinases
Heterografts
Proteomics
Toxicology
DNA Damage
Colorectal Neoplasms
Lung Neoplasms
Cell Cycle
Cell Death
Therapeutics
Clinical Trials
Cell Line
Growth

Cite this

A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. / Orienti, Isabella; Francescangeli, Federica; De Angelis, Maria Laura; Fecchi, Katia; Bongiorno-Borbone, Lucilla; Signore, Michele; Peschiaroli, Angelo; Boe, Alessandra; Bruselles, Alessandro; Costantino, Angelita; Eramo, Adriana; Salvati, Valentina; Sette, Giovanni; Contavalli, Paola; Zolla, Lello; Oki, Toshihiko; Kitamura, Toshio; Spada, Massimo; Giuliani, Alessandro; Baiocchi, Marta; La Torre, Filippo; Melino, Gerry; Tartaglia, Marco; De Maria, Ruggero; Zeuner, Ann.

In: Cell death & disease, Vol. 10, No. 7, 23.07.2019, p. 529.

Research output: Contribution to journalArticle

Orienti, Isabella ; Francescangeli, Federica ; De Angelis, Maria Laura ; Fecchi, Katia ; Bongiorno-Borbone, Lucilla ; Signore, Michele ; Peschiaroli, Angelo ; Boe, Alessandra ; Bruselles, Alessandro ; Costantino, Angelita ; Eramo, Adriana ; Salvati, Valentina ; Sette, Giovanni ; Contavalli, Paola ; Zolla, Lello ; Oki, Toshihiko ; Kitamura, Toshio ; Spada, Massimo ; Giuliani, Alessandro ; Baiocchi, Marta ; La Torre, Filippo ; Melino, Gerry ; Tartaglia, Marco ; De Maria, Ruggero ; Zeuner, Ann. / A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. In: Cell death & disease. 2019 ; Vol. 10, No. 7. pp. 529.
@article{850fb956e79948b6b320481a7a911c4d,
title = "A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors",
abstract = "Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological profile, but also by a low bioavailability that hindered its clinical efficacy in former clinical trials. We developed a new formulation of fenretinide complexed with 2-hydroxypropyl-beta-cyclodextrin (nanofenretinide) characterized by an increased bioavailability and therapeutic efficacy. Nanofenretinide was active in cell lines derived from multiple solid tumors, in primary spheroid cultures and in xenografts of lung and colorectal cancer, where it inhibited tumor growth independently from the mutational status of tumor cells. A global profiling of pathways activated by nanofenretinide was performed by reverse-phase proteomic arrays and lipid analysis, revealing widespread repression of the mTOR pathway, activation of apoptotic, autophagic and DNA damage signals and massive production of dihydroceramide, a bioactive lipid with pleiotropic effects on several biological processes. In cells that survived nanofenretinide treatment there was a decrease of factors involved in cell cycle progression and an increase in the levels of p16 and phosphorylated p38 MAPK with consequent block in G0 and early G1. The capacity of nanofenretinide to induce cancer cell death and quiescence, together with its elevated bioavailability and broad antitumor activity indicate its potential use in cancer treatment and chemoprevention.",
author = "Isabella Orienti and Federica Francescangeli and {De Angelis}, {Maria Laura} and Katia Fecchi and Lucilla Bongiorno-Borbone and Michele Signore and Angelo Peschiaroli and Alessandra Boe and Alessandro Bruselles and Angelita Costantino and Adriana Eramo and Valentina Salvati and Giovanni Sette and Paola Contavalli and Lello Zolla and Toshihiko Oki and Toshio Kitamura and Massimo Spada and Alessandro Giuliani and Marta Baiocchi and {La Torre}, Filippo and Gerry Melino and Marco Tartaglia and {De Maria}, Ruggero and Ann Zeuner",
year = "2019",
month = "7",
day = "23",
doi = "10.1038/s41419-019-1775-y",
language = "English",
volume = "10",
pages = "529",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors

AU - Orienti, Isabella

AU - Francescangeli, Federica

AU - De Angelis, Maria Laura

AU - Fecchi, Katia

AU - Bongiorno-Borbone, Lucilla

AU - Signore, Michele

AU - Peschiaroli, Angelo

AU - Boe, Alessandra

AU - Bruselles, Alessandro

AU - Costantino, Angelita

AU - Eramo, Adriana

AU - Salvati, Valentina

AU - Sette, Giovanni

AU - Contavalli, Paola

AU - Zolla, Lello

AU - Oki, Toshihiko

AU - Kitamura, Toshio

AU - Spada, Massimo

AU - Giuliani, Alessandro

AU - Baiocchi, Marta

AU - La Torre, Filippo

AU - Melino, Gerry

AU - Tartaglia, Marco

AU - De Maria, Ruggero

AU - Zeuner, Ann

PY - 2019/7/23

Y1 - 2019/7/23

N2 - Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological profile, but also by a low bioavailability that hindered its clinical efficacy in former clinical trials. We developed a new formulation of fenretinide complexed with 2-hydroxypropyl-beta-cyclodextrin (nanofenretinide) characterized by an increased bioavailability and therapeutic efficacy. Nanofenretinide was active in cell lines derived from multiple solid tumors, in primary spheroid cultures and in xenografts of lung and colorectal cancer, where it inhibited tumor growth independently from the mutational status of tumor cells. A global profiling of pathways activated by nanofenretinide was performed by reverse-phase proteomic arrays and lipid analysis, revealing widespread repression of the mTOR pathway, activation of apoptotic, autophagic and DNA damage signals and massive production of dihydroceramide, a bioactive lipid with pleiotropic effects on several biological processes. In cells that survived nanofenretinide treatment there was a decrease of factors involved in cell cycle progression and an increase in the levels of p16 and phosphorylated p38 MAPK with consequent block in G0 and early G1. The capacity of nanofenretinide to induce cancer cell death and quiescence, together with its elevated bioavailability and broad antitumor activity indicate its potential use in cancer treatment and chemoprevention.

AB - Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological profile, but also by a low bioavailability that hindered its clinical efficacy in former clinical trials. We developed a new formulation of fenretinide complexed with 2-hydroxypropyl-beta-cyclodextrin (nanofenretinide) characterized by an increased bioavailability and therapeutic efficacy. Nanofenretinide was active in cell lines derived from multiple solid tumors, in primary spheroid cultures and in xenografts of lung and colorectal cancer, where it inhibited tumor growth independently from the mutational status of tumor cells. A global profiling of pathways activated by nanofenretinide was performed by reverse-phase proteomic arrays and lipid analysis, revealing widespread repression of the mTOR pathway, activation of apoptotic, autophagic and DNA damage signals and massive production of dihydroceramide, a bioactive lipid with pleiotropic effects on several biological processes. In cells that survived nanofenretinide treatment there was a decrease of factors involved in cell cycle progression and an increase in the levels of p16 and phosphorylated p38 MAPK with consequent block in G0 and early G1. The capacity of nanofenretinide to induce cancer cell death and quiescence, together with its elevated bioavailability and broad antitumor activity indicate its potential use in cancer treatment and chemoprevention.

U2 - 10.1038/s41419-019-1775-y

DO - 10.1038/s41419-019-1775-y

M3 - Article

C2 - 31332161

VL - 10

SP - 529

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 7

ER -